BIIB vs. DHR: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BIIB and DHR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BIIB | DHR |
|---|---|---|
| Company Name | Biogen Inc. | Danaher Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 20.38 billion USD | 151.37 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | September 17, 1991 | December 29, 1978 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BIIB and DHR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BIIB | DHR |
|---|---|---|
| 5-Day Price Return | 3.00% | 0.56% |
| 13-Week Price Return | 7.38% | 7.63% |
| 26-Week Price Return | 0.39% | 3.84% |
| 52-Week Price Return | -32.55% | -22.07% |
| Month-to-Date Return | 8.59% | 7.22% |
| Year-to-Date Return | -9.11% | -7.91% |
| 10-Day Avg. Volume | 1.42M | 3.11M |
| 3-Month Avg. Volume | 1.49M | 4.00M |
| 3-Month Volatility | 31.01% | 26.58% |
| Beta | 0.09 | 0.79 |
Profitability
Return on Equity (TTM)
BIIB
9.04%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
BIIB’s Return on Equity of 9.04% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
DHR
6.69%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
DHR’s Return on Equity of 6.69% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BIIB
15.31%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
BIIB’s Net Profit Margin of 15.31% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
DHR
14.21%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
DHR’s Net Profit Margin of 14.21% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
BIIB
20.80%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 20.80% places BIIB in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
DHR
18.43%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
DHR’s Operating Profit Margin of 18.43% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | BIIB | DHR |
|---|---|---|
| Return on Equity (TTM) | 9.04% | 6.69% |
| Return on Assets (TTM) | 5.43% | 4.28% |
| Net Profit Margin (TTM) | 15.31% | 14.21% |
| Operating Profit Margin (TTM) | 20.80% | 18.43% |
| Gross Profit Margin (TTM) | 75.43% | 59.72% |
Financial Strength
Current Ratio (MRQ)
BIIB
2.50
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
BIIB’s Current Ratio of 2.50 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
DHR
1.62
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
DHR’s Current Ratio of 1.62 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BIIB
0.36
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
BIIB’s Debt-to-Equity Ratio of 0.36 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
DHR
0.33
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
DHR’s Debt-to-Equity Ratio of 0.33 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BIIB
4.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
BIIB’s Interest Coverage Ratio of 4.35 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
DHR
22.31
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
DHR’s Interest Coverage Ratio of 22.31 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BIIB | DHR |
|---|---|---|
| Current Ratio (MRQ) | 2.50 | 1.62 |
| Quick Ratio (MRQ) | 1.79 | 1.10 |
| Debt-to-Equity Ratio (MRQ) | 0.36 | 0.33 |
| Interest Coverage Ratio (TTM) | 4.35 | 22.31 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
DHR
0.54%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Yield of 0.54% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
DHR
23.85%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Payout Ratio of 23.85% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | BIIB | DHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.54% |
| Dividend Payout Ratio (TTM) | 0.00% | 23.85% |
Valuation
Price-to-Earnings Ratio (TTM)
BIIB
13.27
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Biotechnology industry, BIIB’s P/E Ratio of 13.27 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
DHR
44.40
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
DHR’s P/E Ratio of 44.40 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BIIB
2.03
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, BIIB’s P/S Ratio of 2.03 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
DHR
6.31
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
DHR’s P/S Ratio of 6.31 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
BIIB
1.04
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
BIIB’s P/B Ratio of 1.04 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
DHR
2.72
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
DHR’s P/B Ratio of 2.72 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BIIB | DHR |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 13.27 | 44.40 |
| Price-to-Sales Ratio (TTM) | 2.03 | 6.31 |
| Price-to-Book Ratio (MRQ) | 1.04 | 2.72 |
| Price-to-Free Cash Flow Ratio (TTM) | 11.00 | 31.17 |